ReviewCost effectiveness and resource allocation : C/E2023

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis.

Zahra Goudarzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.